US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

264.97

-5.9600-2.20%

Pre-market: 264.970.00000.00%04:00 EDT

Volume:71.47K

Turnover:18.95M

Market Cap:2.90B

PE:31.01

High:273.10

Open:273.10

Low:262.30

Close:270.93

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:1.06

T/O Rate:0.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.02

Loading ...

Overview Company News Filings

Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug

THOMSON REUTERS

Alkermes announces Phase 1b results of ALKS 7290 in ADHD

Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD

Bruker Wins over $6 Million UC Berkeley Order for High-Field NMR Systems

Bruker Receives Order for High-Field Nmr Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at Uc Berkeley

THOMSON REUTERS

Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd

THOMSON REUTERS

Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)

THOMSON REUTERS

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS

Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72

Alkermes Files Form 3 for Director Anne Clem Whitaker`

Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)

Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026

THOMSON REUTERS

Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

THOMSON REUTERS

FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares

Bruker Nano Exec VP Mark Munch Sells 2,000 Bruker Shares for $105,740

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/FBT/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":264.97,"timestamp":1791316800000,"preClose":270.93,"halted":0,"volume":71469,"hourTrading":{"tag":"盘前","latestPrice":264.97,"preClose":264.97,"latestTime":"04:00 EDT","volume":1,"amount":264.97,"timestamp":1791360025951,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.021998302144465284,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Pre-Mkt","change":-5.96,"latestTime":"10-07 06:11:40 EDT","open":273.1,"high":273.1,"low":262.3,"amount":18953471.5965,"amplitude":0.039863,"askPrice":270.78,"askSize":200,"bidPrice":262,"bidSize":160,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791379800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":264.97,"sharesOutstanding":11450002,"nav":270.76,"aum":2951284541.52,"bidAskSpread":0.001073,"preHourTrading":{"tag":"盘前","latestPrice":264.97,"preClose":264.97,"latestTime":"04:00 EDT","volume":1,"amount":264.97,"timestamp":1791360025951,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":264.97,"preClose":264.97,"latestTime":"19:30 EDT","volume":23,"amount":6096.091,"timestamp":1791329403228,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0580946017177977,"impliedVol":0.2498,"impliedVolPercentile":0.924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.0580946017177977,"shares":10950002,"dividePrice":0,"high":273.1,"amplitude":0.039863,"preClose":270.93,"low":262.3,"week52Low":182.08,"pbRate":"1.04","psRate":"699.94","week52High":275.23,"institutionHeld":0,"latestPrice":264.97,"committee":-0.111111,"eps":8.545272,"divideRate":0,"volume":71469,"delay":0,"ttmEps":8.545272,"open":273.1,"prevYearClose":206.52,"prevWeekClose":266.44,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":272.58,"twentyDayClose":265.78,"sixtyDayClose":247.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669150485","title":"Alkermes Shares Rise 6.5% Premarket After Positive Results from Early-Stage Study of Adhd Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150485?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:07","pubTimestamp":1789988867,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","PSIL","ALKS","BK4139","FBT","IBRN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669916887","title":"Alkermes announces Phase 1b results of ALKS 7290 in ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669916887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669916887?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:05","pubTimestamp":1789988737,"startTime":"0","endTime":"0","summary":"Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alkermes-announces-phase-1b-results-of-alks-7290-in-adhd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4139","PSIL","ABVC","PSCH","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669415062","title":"Alkermes Reports Positive Phase 1b Proof-of-Concept Data for ALKS 7290 in Adult ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2669415062","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669415062?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988517,"startTime":"0","endTime":"0","summary":"Alkermes reports positive Phase 1b proof-of-concept data for ALKS 7290 in adult ADHDAlkermes reported positive Phase 1b topline results for ALKS 7290 in adults with ADHD; results have already been pre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2WW99h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","PSIL","ALKS","MEDX","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150625","title":"Bruker Wins over $6 Million UC Berkeley Order for High-Field NMR Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150625","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150625?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:01","pubTimestamp":1789988463,"startTime":"0","endTime":"0","summary":"Bruker wins over $6 million UC Berkeley order for high-field NMR systemsBruker received a multi-system order from the University of California, Berkeley for high-field NMR instrumentation at the Pines","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDLb5g2fh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TINY","BRKR","FBT","BK4121","LU1815336091.USD","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150544","title":"Bruker Receives Order for High-Field Nmr Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at Uc Berkeley","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150544?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA4FDCZM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BRKR","LU1815336091.USD","LU0757428866.USD","BK4121","TINY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669505181","title":"Alkermes -Alks 7290 Generally Well Tolerated at All Doses in Healthy Volunteers and Adults with Adhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2669505181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669505181?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","IBRN","PSIL","PSCH","BK4139","ALKS","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150548","title":"Alkermes Announces Positive Phase 1B Results Demonstrating Clinical Proof-of-Concept for Alks 7290 in Adults with Attention-Deficit Hyperactivity Disorder (Adhd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150548?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","PSIL","BK4139","PSCH","IBRN","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669150512","title":"Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2669150512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669150512?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:00","pubTimestamp":1789988400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA9RZ6JR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","PSIL","ALKS","MEDX","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668358979","title":"Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2668358979","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668358979?lang=en_us&edition=fundamental","pubTime":"2026-09-19 07:54","pubTimestamp":1789775650,"startTime":"0","endTime":"0","summary":"Corcept President, Oncology Roberto Wandenkolk Vieira sells 296 shares for $29,842.72Corcept’s President, Oncology Roberto Wandenkolk Vieira sold 296 common shares on Sep. 16, 2026 at $100.82.He repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL5zJb0H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept President, Oncology Roberto Wandenkolk Vieira Sells 296 Shares for $29,842.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","BK4532","LU0566484027.USD","CORT","BK4007","FBT","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668789973","title":"Alkermes Files Form 3 for Director Anne Clem Whitaker`","url":"https://stock-news.laohu8.com/highlight/detail?id=2668789973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668789973?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:48","pubTimestamp":1789764537,"startTime":"0","endTime":"0","summary":"Alkermes files Form 3 for director Anne Clem Whitaker`Alkermes director Anne Clem Whitaker filed a Form 3 initial statement of beneficial ownership dated Sept. 14, 2026.Disclaimer:This news brief was ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL7wyxYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","PSIL","ALKS","MEDX","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668273689","title":"Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668273689","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668273689?lang=en_us&edition=fundamental","pubTime":"2026-09-19 00:30","pubTimestamp":1789749010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corcept Therapeutics (CORT) and Xenon (XENE) with bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-corcept-therapeutics-cort-xenon-xene-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT","HCSG","SBIO","XLV","BK4585","BK4581","BK4588","LU0029874061.USD","XBI","IBRN","BK4137","LABU","LU0128526141.USD","BK4139","BK4007","LU1559883803.SGD","LU0566484027.USD","XENE","BK4532","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923679","title":"Corcept Says EU CHMP Backs Lifyorli Combo for Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923679","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923679?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:01","pubTimestamp":1789732903,"startTime":"0","endTime":"0","summary":"Corcept says EU CHMP backs Lifyorli combo for platinum-resistant ovarian cancerEU drug regulator’s CHMP backed marketing authorization for Corcept’s Lifyorli (relacorilant) with nab-paclitaxel in plat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDLcd4Vr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4532","PSCH","CORT","BK4007","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923688","title":"Corcept Therapeutics Incorporated - Ec to Issue Final Approval Decision in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923688","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923688?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","FBT","LU0566484027.USD","CORT","BK4532","PSCH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923684","title":"Corcept Announces Chmp Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923684?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:00","pubTimestamp":1789732800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUA4Q98SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","LU1559883803.SGD","PSCH","LU0566484027.USD","BK4532","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668991067","title":"FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A","url":"https://stock-news.laohu8.com/highlight/detail?id=2668991067","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668991067?lang=en_us&edition=fundamental","pubTime":"2026-09-18 02:35","pubTimestamp":1789670130,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration approved Fayuvi, which it calls “the first treatment for pediatric patients with mucopolysaccharidosis type I...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-approves-ultragenyx-gene-therapy-for-sanfilippo-syndrome-type-a-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","CNCR","SYNB","IBB","LABU","BK4585","TBXU","LFSC","BK4588","GNOM","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996274","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996274?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648219,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS), Twist Bioscience (TWST) and Medpa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-twist-bioscience-twst-and-medpace-holdings-medp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","LU0029874061.USD","TWST","FBT","IBRN","LU2065171311.SGD","BK4581","MEDX","BK4137","LU2065169927.USD","ARKG","BK4585","BK4139","PSCH","HCSG","LU0128526141.USD","XLV","IDNA","GNOM","XBI","BK4588","LU2065170008.USD","MEDP","BK4121","LU2065171402.SGD","WDNA","LABU","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668115964","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668115964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668115964?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:50","pubTimestamp":1789645810,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-veracyte-vcyt-iqvia-holdings-iqv-and-chemed-che-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-veracyte-vcyt-iqvia-holdings-iqv-and-chemed-che-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0980610538.SGD","IE00BLDYK493.USD","BK4137","BK4585","IE00B64QTZ34.USD","LU2413666004.HKD","XBI","LU1989764748.USD","EKG","LU1721427968.SGD","FBT","LU1620156130.USD","BK4139","LU0528227936.USD","LU0648001328.SGD","LU0029874061.USD","LU0477156797.USD","LU1543694498.USD","LU0130518102.USD","HCSG","BK4121","BK4588","LU1165135440.EUR","LU1989764664.SGD","BK4581","LU0198837287.USD","LU1201861249.SGD","LU0130103400.USD","LU0128526141.USD","LU2413665964.HKD","LU1261432733.SGD","LU1201861165.SGD","HEAL","LU0648000940.SGD","LU1791710400.SGD","IQV","LABU","LU0882574055.USD","LU1596574779.USD","LU1620156213.USD","BK4530","VCYT","LU0130517989.USD","XLV","LU0130102774.USD","LU0477156953.USD","BK4196","CHE","LU1791710582.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668936994","title":"Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2668936994","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668936994?lang=en_us&edition=fundamental","pubTime":"2026-09-17 05:35","pubTimestamp":1789594520,"startTime":"0","endTime":"0","summary":"Longeveron (LGVN) announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestroc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/longeverons-laromestrocel-did-not-meet-primary-endpoint-in-phase-2b-hlhs-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","IBBQ","IDNA","IBB","BK4585","BK4139","GDOC","MEDX","LGVN","NVIB","HYLG","CNCR","FBT","SYNB","BK4588","GNOM","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668693589","title":"Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668693589","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668693589?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:31","pubTimestamp":1789590707,"startTime":"0","endTime":"0","summary":"Corcept director James N. Wilson disposes of $1.11 million in common sharesCorcept director James N. Wilson reported selling 10,000 common shares on Sept. 15, 2026.Sales prices ranged from USD 110.27 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL5LXKps:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Director James N. Wilson Disposes of $1.11 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","CORT","BK4007","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668933265","title":"Bruker Nano Exec VP Mark Munch Sells 2,000 Bruker Shares for $105,740","url":"https://stock-news.laohu8.com/highlight/detail?id=2668933265","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668933265?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:16","pubTimestamp":1789589780,"startTime":"0","endTime":"0","summary":"Bruker Nano Exec VP Mark Munch sells 2,000 Bruker shares for $105,740Mark Munch, executive vice president and president of Bruker Nano, sold 2,000 Bruker common shares at USD 52.87 on Sep. 15, 2026.He","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL78KKS2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Bruker Nano Exec VP Mark Munch Sells 2,000 Bruker Shares for $105,740","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","BK4121","TINY","LU1815336091.USD","LU0757428866.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}